Welcome to your weekend Biotech & Pharma Stock Market Recap.

What’s to be covered in this hallowed scroll:

1. Overview of the biotech & pharma stocks that had the best & worst weeks (as measured by % change in price)

2. We’ll give you a calendar of whose announcing earnings in the upcoming week - and if they’re before the markets open (BMO) or after markets close (AMC).

3. One more thing we’ll have in future weeks - a recap of the more notable earnings calls the week previous.

Lastly - all three of the above will have sub-sections divided by:

1. Biotechnology (life sciences and the like)

2. Drug Manufacturers - General (this one includes big pharma)

3. Drug Manufacturers - Specialty and Pharma (everyone else that makes drugs, and then some)

And last thing - everything is in USD unless otherwise stated!

This weekend edition is a new feature at TLDR Biotech, so I’d love to get your feedback.

(You can also reach out to me on LinkedIn)

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

Biotechnology

Annovis Bio (ANVS) shot up due to positive Ph3 Parkinson’s data (not good enough to be back in the green YTD though).

Longboard Pharmaceuticals (LBPH) has also had a great year so far, gapping up in January on Ph1b/2a epilepsy date, while their climb over the last few weeks isn’t exactly clear (their breakthrough designation announcement is in the middle of this rally).

eFFECTOR Therapeutics (EFTR) continues its death rattle after their shutdown announcement late last month.

ANEW Medical (EFTR) took an initial dive in June due to an M&A, then gapped up again on a new patent acquisition - their drop this last week is likely a correction to this patent news.

Upcoming Biotechnology Earnings Calls

Theratechnologies (THTX) hasn’t had the greatest year thus far, with an FDA rejection in late February.

AFFILIATE
Finviz: ✨Financial Visualizations🤩

I’m using Finviz to put together these compilations - it’s the easiest way to visualize and assess multiple stocks within the same industry (like within biotech).

If this is down your alley, you can check it out for free using my Affiliate link.

Drug Manufacturers - General

Grifols (GRFS) likely jumped this week not just on debt financing news, but also on news of their new CFO.

Upcoming Drug Manufacturers - General Earnings Calls

No earnings call next week for this group!

Instead, why not learn about the history of blood letting as a therapy?

Drug Manufacturers - Specialty & Generic

For Sonoma Pharmaceuticals (SNOA), they might be surging purely on “momentum” as opposed to something more substantial.

A similar situation with Bright Green Corp (BGXX) but in the opposite direction, as the microcap stock experiences volatile movements on not much news.

On the more substantial side, Pacira Biosciences (PCRX) tumbled due to the FDA approving a generic version of their best-selling commercial asset.

Upcoming Drug Manufacturers - Specialty & Generic Earnings Calls

No earnings next week for this week group!

Instead, why not check-out my hot take on Sarepta Therapeutic’s recent DMD approval?

That’s all for now - don’t get roasted this weekend!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here